Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Gabrielle Lurie/The San Francisco Chronicle via Getty Images

A Baltimore plant ruined a batch of "drug substance" that would have gone into millions of doses of Johnson & Johnson's coronavirus vaccine — but sources familiar with the process say the setback ultimately may not be that bad.

The big picture: Anything that could slow down the vaccine production process is not good news, especially for the one-shot J&J vaccine. But some experts said the company and the overall U.S. vaccination effort will likely be able to recover quickly.

Driving the news: The New York Times first reported that workers at the Baltimore plant, run by Emergent BioSolutions, ruined a batch of "drug substance" — material that makes up a vaccine, but isn't yet bottled — when workers there accidentally contaminated the batch.

  • The NYT reported that the accident ruined about 15 million doses of J&J's vaccine, although sources cautioned that it can be difficult to predict how many doses a batch of drug substance will ultimately yield.

What's next: The contamination doesn't affect vaccine doses that have already been manufactured, and this plant has been building a stockpile of the substance, sources said. Only one batch is known to have been contaminated.

  • "Ultimately, it's a blip, and I think everyone expected there to be issues somewhere at some point...it's not nothing, but it's not perhaps as big as it's been made out to be," a former Operation Warp Speed official told me.
  • Manufacturers often produce more of this particular substance than they need, so this part of the supply chain may be able to catch up while the later stages of the manufacturing process keep moving.

Yes, but: The Baltimore facility hadn't yet gotten authorization from the FDA to manufacture the substance. It was building up its supplies in anticipation of getting that green light.

  • It will only be able to get back on track if the green light still comes — and this incident could jeopardize that.
  • The contamination has prompted the FDA to delay the plant's approval, Politico first reported, and Axios confirmed.
  • So far, J&J has produced all of its vaccine doses using drug substance produced overseas. This is the only plant making the substance in the U.S., and was supposed to produce all further domestic shipments of the Johnson & Johnson vaccine in the immediate future, the NYT reported.
  • So if these problems are severe enough to cost the plant its regulatory OK, the supply problems could get more serious.

A source close to the process said J&J has committed enormous resources to fix the process.

The bottom line: A serious setback in J&J's production would absolutely be bad news for the global vaccination effort, which is running short on supply. But sources are optimistic that even under worst case scenarios, the U.S. effort won't be affected much.

  • A source close to the process said while it's important for J&J to fix its process, Pfizer and Moderna are far enough ahead of schedule to ensure there will be enough vaccine available for every adult who wants one by the end of May, even without any more J&J doses.

Go deeper

Mar 31, 2021 - Health

Baltimore plant ruins 15 million Johnson & Johnson coronavirus vaccines

Vials of Johnson & Johnson's coronavirus vaccine in Oakland, California, on March 26. Photo: Gabrielle Lurie/The San Francisco Chronicle via Getty Images

A Baltimore plant run by Emergent BioSolutions that produces coronavirus vaccines ruined a batch of Johnson & Johnson’s vaccine, according to a statement released by Johnson & Johnson Wednesday.

Why it matters: The plant, which was projected to produce and ship tens of millions of Johnson & Johnson doses next month, must now cease producing the one-dose vaccine while the Food and Drug Administration investigates the error, the New York Times first reported. Axios confirmed the report is accurate.

Updated Oct 21, 2021 - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: U.S. releases updated vaccination, testing rules for foreign travelers — Moderna says COVID vaccine shows strong immune response in kids — COVID vaccines for kids are getting closer — A choose-your-own COVID booster adventure
  2. Health: Unvaccinated athletes face 21-day quarantine at Beijing Olympics
  3. Politics: Study reveals disparities in hospitals' COVID funds — DeSantis touts bonuses for unvaccinated police who relocate to Florida — Puerto Rico leads U.S. vaccination rates
  4. Education: Benefits of COVID vaccine for children outweigh risks, FDA says — Education secretary reveals limits to Biden’s mask push on states — LA extends deadline for school employee vaccinations
  5. Variant tracker: Where different strains are spreading.
Mar 31, 2021 - World

France to close schools for 3 weeks, impose domestic travel ban as COVID surges

French President Emmanuel Macron. Photo: Ludovic Marin/AFP via Getty Images

France is requiring schools nationwide to close for three weeks and is imposing a domestic travel ban to help control the "accelerating" coronavirus pandemic, President Emmanuel Macron said Wednesday.

Driving the news: It's the third lockdown for the country since the pandemic began, and a departure from the recent regional approach. The move comes as Europe battles a third wave of the coronavirus, driven in part by more transmissible variants.